Fidelity Select Consumer Discretionary Portfolio: Q1 2026 Performance Analysis
Finance

Fidelity Select Consumer Discretionary Portfolio: Q1 2026 Performance Analysis

authorBy Michele Ferrero
DateJun 05, 2026
Read time3 min
This report provides a detailed overview of the Fidelity Select Consumer Discretionary Portfolio's performance during the first quarter of 2026, highlighting key market trends, significant contributing and detracting factors, and strategic adjustments made to the portfolio. It examines the broader market context for consumer discretionary stocks and offers insights into the investment decisions shaping the fund's direction.

Navigating Volatility: A Strategic Review of Consumer Discretionary Investments

Q1 2026 Performance Snapshot: Outperforming in a Challenging Market

In the first quarter of 2026, the Fidelity Select Consumer Discretionary Portfolio Retail Class achieved a return of -8.17%, demonstrating a modest outperformance compared to its benchmark, the MSCI U.S. IMI Consumer Discretionary 25/50 Index. This period was characterized by a broader market downturn in consumer discretionary stocks, which saw an -8.59% decline, trailing the S&P 500 Index's -4.33% result. Factors such as a decline in consumer confidence and persistent inflationary pressures contributed to this challenging market environment.

Automotive Sector Headwinds: The Tesla Experience

The automotive manufacturing sector faced significant challenges during the quarter, with major players like Tesla experiencing declines. Increased competition from lower-cost electric vehicle manufacturers and investor skepticism regarding Tesla's ventures into artificial intelligence and robotaxi initiatives adversely impacted the stock's performance.

Discount Retail's Resilience: The Success of Ross Stores

Conversely, discount retailers proved to be a bright spot. Ross Stores, in particular, benefited from its effective merchandising strategies and a surge in demand from value-seeking consumers. This led to robust traffic growth and positioned the company as a top positive contributor to the portfolio's relative performance.

Challenges in the Home Furnishings and Entertainment Sectors

Somnigroup International was a notable detractor from performance, reporting fourth-quarter 2025 revenue figures that fell short of analyst expectations and providing a fiscal 2026 adjusted earnings per share guidance below market estimates. This highlighted the volatility within certain consumer discretionary sub-sectors.

Strategic Portfolio Adjustments: New Holdings and Exits

Fidelity actively managed the portfolio by establishing a new position in Bob's Discount Furniture, signaling confidence in the company's prospects. Additionally, stakes in Carnival and Churchill Downs were increased. In a move to optimize the portfolio, positions in Flutter Entertainment and Ulta Beauty were entirely divested.

Market Overview: Consumer Discretionary Amidst Economic Shifts

The first quarter of 2026 presented a complex landscape for consumer discretionary stocks, characterized by softening consumer sentiment and ongoing inflation. Despite these headwinds, strategic asset allocation and focused stock selection enabled the Fidelity Select Consumer Discretionary Portfolio to navigate the market effectively, achieving outperformance relative to its specialized index.

More Articles
Finance
SGA U.S. Large Cap Growth Fund Q1 2026 Performance Analysis
The SGA U.S. Large Cap Growth portfolio experienced an -11.1% gross return in Q1 2026, trailing the Russell 1000 Growth Index. This underperformance largely stemmed from a divergence between immediate AI beneficiaries and companies perceived to be negatively impacted by AI. The fund strategically added Mastercard due to its valuation and divested Gartner and UnitedHealth due to fundamental shifts. Despite market volatility, the portfolio targets 13% revenue and 19% earnings growth over the next three years, demonstrating a commitment to long-term compounding.
By Fareed ZakariaJun 05, 2026
Finance
Aquestive Therapeutics Faces Setback with Anaphylm, Downgraded to Hold
Aquestive Therapeutics has been downgraded to Hold following the FDA's Complete Response Letter for Anaphylm, citing deficiencies in human factors studies. The company plans to resubmit the NDA in Q3 2026, targeting potential approvals in multiple regions by late 2027. Despite a strong cash position and new debt facility, competition and market adoption concerns temper confidence in Anaphylm's projected peak sales, leading to a cautious outlook.
By David RubensteinJun 04, 2026
Finance
NRG Energy's Sustained Growth Trajectory
NRG Energy, Inc. is a compelling investment opportunity due to its strong growth catalysts and attractive valuation. The company's smart home division, despite contributing only 7% of total revenue, accounts for 23.3% of its economic gross margin and is experiencing rapid expansion. Management projects a significant increase in EBITDA for 2026, driven by rising power prices and increasing demand from data centers. NRG's conservative leverage profile further supports its ability to fund new investments and growth initiatives, including a joint venture aiming to add 3 GW of capacity by 2032.
By David RubensteinJun 04, 2026
Finance
Navigating the Current Market Trajectory: Is it Time to Reassess Equity Allocations?
The S&P 500's current valuations are exceptionally high, with both the cyclically adjusted P/E and market cap-to-GDP ratios reaching historical peaks. The market's upward trend is largely propelled by a tech-driven, AI-centric narrative, relying on optimistic future growth predictions that allow for minimal error. Furthermore, the earnings yield of equities now falls short of Treasury yields, leading to a reduced equity risk premium and weakening the argument for long-term equity investments. This situation suggests a strategic move to secure profits and seek alternative investment avenues.
By Nouriel RoubiniJun 04, 2026
Finance
Chevron's Promising Future Despite Market Fluctuations
Chevron (CVX) has been re-evaluated as a "buy" with an increased price target, driven by rising oil prices and significant production growth in the first quarter. The company maintains its ambitious 2026 targets, including 7-10% production growth, $18B-$19B in annual organic capital expenditure, and $3B-$4B in cost reductions. With strong EPS growth projections and an attractive free cash flow yield of 5.3%, Chevron presents a compelling investment opportunity, though potential risks such as geopolitical developments and refining competition warrant consideration.
By Nouriel RoubiniJun 04, 2026